[1] 陈杰, 曹元杰, 朱莉, 等.  尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌的临床观察[J]. 中华医学杂志, 2021, 101(8): 597-601.   doi: 10.3760/cma.j.cn112137-20201104-03011
Chen J, Cao YJ, Zhu L, et al.  Clinical observational study of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer[J]. Natl Med J China, 2021, 101(8): 597-601.   doi: 10.3760/cma.j.cn112137-20201104-03011
[2] Gadducci A, Cosio S.  Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research[J]. Anticancer Res, 2020, 40(9): 4819-4828.   doi: 10.21873/anticanres.14485
[3] 王利宁, 杨美华.  适形调强放疗同步紫杉醇脂质体与顺铂治疗局部晚期宫颈癌的疗效比较[J]. 中国基层医药, 2022, 29(8): 1141-1145.   doi: 10.3760/cma.j.cn341190-20210202-00159
Wang LN, Yang MH.  Efficacy of conformal intensity-modulated radiotherapy with paclitaxel liposome versus cisplatin in the treatment of locally advanced cervical cancer[J]. Chin J Prim Med Pharm, 2022, 29(8): 1141-1145.   doi: 10.3760/cma.j.cn341190-20210202-00159
[4] Huang HQ, Quan Y, Qi XR, et al.  Neoadjuvant chemotherapy with paclitaxel plus cisplatin before radical surgery for locally advanced cervical cancer during pregnancy: a case series and literature review[J]. Medicine (Baltimore), 2021, 100(32): e26845-.   doi: 10.1097/MD.0000000000026845
[5] Bhatla N, Berek JS, Fredes MC, et al.  Revised FIGO staging for carcinoma of the cervix uteri[J]. Int J Gynaecol Obstet, 2019, 145(1): 129-135.   doi: 10.1002/ijgo.12749
[6] 中国抗癌协会妇科肿瘤专业委员会.  子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 474-489.   doi: 10.19401/j.cnki.1007-3639.2021.06.06
Chinese Anti-Cancer Association Gynecological Tumor Professional Committee.  Guidelines for diagnosis and treatment of cervical cancer (2021 edition)[J]. China Oncol, 2021, 31(6): 474-489.   doi: 10.19401/j.cnki.1007-3639.2021.06.06
[7] Eisenhauer EA, Therasse P, Bogaerts J, et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.   doi: 10.1016/j.ejca.2008.10.026
[8]

U. S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0[R]. Washington: U. S. Department of Health and Human Services, 2009.
[9] 龙书敬, 王军, 王祎, 等.  急性放射性心脏损伤不同分级标准比较研究[J]. 中华肿瘤防治杂志, 2014, 21(6): 469-472.   doi: 10.3969/j.issn.1673-5269.2014.06.016
Long SJ, Wang J, Wang Y, et al.  Comparison of different classification criteria about acute radiation-induced heart damage[J]. Chin J Cancer Prev Treat, 2014, 21(6): 469-472.   doi: 10.3969/j.issn.1673-5269.2014.06.016
[10] Yavas G, Yavas C, Sen E, et al.  Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer[J]. Int J Gynecol Cancer, 2019, 29(1): 42-47.   doi: 10.1136/ijgc-2018-000022
[11]

刘超霞, 冉晓敏, 张克强, 等. 淋巴结转移的局部晚期宫颈癌行PD-1抑制剂联合同步放化疗的疗效及安全性研究[J]. 中国肿瘤临床, 2023, 50(8): 418-422. DOI:10.12354/j.issn.1000-8179.2023.20221351.

Liu CX, Ran XM, Zhang KQ, et al. Efficacy and safety of programmed cell death-1 inhibitor combined with concurrent chemoradiotherapy for locally advanced cervical cancer patients with lymph node metastases[J] Chin J Clin Oncol, 2023, 50 (8): 418-422. DOI: 10.12354/j.issn.1000-8179.2023.20221351.
[12] 冯蓓, 冯艳, 师晓艳.  顺铂同步放疗联合扶正祛邪中药治疗中晚期宫颈癌的研究[J]. 现代中西医结合杂志, 2019, 28(20): 2247-2249, 2253.   doi: 10.3969/j.issn.1008-8849.2019.20.021
Feng B, Feng Y, Shi XY.  Study on simultaneous cisplatin radiotherapy combined with Fuzhengquxie Chinese medicine in the treatment of advanced cervical cancer[J]. Mod J Integr Tradit Chin West Med, 2019, 28(20): 2247-2249, 2253.   doi: 10.3969/j.issn.1008-8849.2019.20.021
[13] 冯静, 林建海, 廖绍光, 等.  宫颈癌术后调强放疗中骨髓抑制与骨髓照射剂量体积的关系[J]. 国际放射医学核医学杂志, 2020, 44(3): 143-150.   doi: 10.3760/cma.j.cn121381-201811039-00002
Feng J, Lin JH, Liao SG, et al.  The relationship between bone marrow suppression and dose volume of bone marrow irradiation for the postoperative cervical cancer patients received intensity modulated radiotherapy[J]. Int J Radiat Med Nucl Med, 2020, 44(3): 143-150.   doi: 10.3760/cma.j.cn121381-201811039-00002
[14] Guo QF, Sun YW, Kong EQ, et al.  Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study[J]. Medicine (Baltimore), 2020, 99(11): e19372-.   doi: 10.1097/MD.0000000000019372
[15]

Drokow EK, Zi L, Qian H, et al. Tolerability, efficacy and feasibility of concurrent gemcitabine and cisplatin (CGP) combined with intensity modulated radiotherapy for loco-regionally advanced carcinoma of the cervix[J/OL]. J Cancer, 2020, 11(9): 2632−2638[2023-05-22]. https://www.jcancer.org/v11p2632.htm. DOI: 10.7150/jca.40276.
[16] 高颜凤, 李文, 庄茜茹.  顺铂和紫杉醇同步放化疗治疗中晚期宫颈癌的效果[J]. 中国当代医药, 2022, 29(33): 76-79.   doi: 10.3969/j.issn.1674-4721.2022.33.020
Gao YF, Li W, Zhuang XR.  Effect of concurrent chemoradiotherapy with cisplatin and paclitaxel in the treatment of advanced cervical cancer[J]. China Mod Med, 2022, 29(33): 76-79.   doi: 10.3969/j.issn.1674-4721.2022.33.020
[17] Liu S, Ren SN, Ding WX, et al.  Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy[J]. Ann Transl Med, 2019, 7(14): 331-.   doi: 10.21037/atm.2019.06.45
[18] 樊涛, 苏书娟, 任金山.  同步推量调强放疗联合TP化疗治疗中晚期宫颈癌的临床研究[J]. 河南医学研究, 2019, 28(3): 439-440.   doi: 10.3969/j.issn.1004-437X.2019.03.022
Fan T, Su SJ, Ren JS.  Clinical study of simultaneous intensity modulated radiotherapy combined with TP chemotherapy in the treatment of advanced cervical cancer[J]. Henan Med Res, 2019, 28(3): 439-440.   doi: 10.3969/j.issn.1004-437X.2019.03.022
[19]

Li H, Fang Y, Gu DY, et al. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase Ⅱ clinical trial[J/OL]. Radiat Oncol, 2022, 17(1): 105[2023-05-22]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-022-02078-3. DOI: 10.1186/s13014-022-02078-3.
[20] 黄伟娟, 高雁荣.  TP化疗方案同步调强放疗治疗47例中、晚期宫颈癌患者的临床研究[J]. 现代医药卫生, 2019, 35(2): 260-261.   doi: 10.3969/j.issn.1009-5519.2019.02.030
Huang WJ, Gao YR.  Clinical study of TP chemotherapy and intensity modulated radiotherapy for 47 patients with moderate and advanced cervical cancer[J]. J Mod Med Health, 2019, 35(2): 260-261.   doi: 10.3969/j.issn.1009-5519.2019.02.030
[21]

He ZY, Li HY, Yan J, et al. A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical[J/OL]. Trials, 2022, 23(1): 556[2023-05-22]. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06489-1. DOI: 10.1186/s13063-022-06489-1.